Penny wise and pound-foolish: Study shows need for second pathologist's opinion

November 30, 1999

A study of more than 6,000 patients by Johns Hopkins researchers found that one or two out of every 100 people who come to larger medical centers for treatment following a biopsy arrive with a diagnosis that's "totally wrong." The results suggest that second opinion pathology exams not only prevent errors, but also save lives and money.

Patients who fail to receive a second pathologist's exam of their biopsied tissue at the incoming hospital or elsewhere "have a small but significant risk of getting the wrong treatment, including surgery or chemotherapy," says pathologist Jonathan L. Epstein, M.D., who led a Hopkins research team. "That's not to mention the psychological trauma of having the wrong prognosis for an illness," he adds, "or the financial burden of the wrong treatment."

The study appears in the December edition of the journal Cancer.

The team compared the original pathologists' reports that 6,171 patients brought to Hopkins prior to treatment, with additional Hopkins-required pathology reports on the incoming patients. Eighty-six of the patients or 1.4 percent were wrongly diagnosed, Epstein says. "That's not a huge number, percentage-wise," he adds, "but the fact that it's as high as it is remains significant, as does the actual number of patients affected across the country."

In reality, the number of patients misdiagnosed in their original pathology reports is probably closer to 2 percent, Epstein says, because the study didn't consider patients wrongly given a clean bill of health from cancer. Such patients don't typically come to a large medical center for treatment.

The researchers tallied only cases in which the difference in the second report would cause a real change in patients' therapy or in their prognosis. More subtle disparities, such as saying a particular type of cancer was somewhat more advanced, weren't part of the study.

In 23 percent of the suspect cases, patients' diagnoses changed from decidedly malignant to decidedly benign, Epstein says. "In 5 percent of the cases, we found the reverse: something would come in as benign condition and we'd find cancer," Epstein says. Other errors included patients diagnosed with the wrong type of cancer: "A patient's original diagnosis might be stomach cancer and we'd find it was a melanoma a case where the patient's future therapy would differ dramatically."

Some of the errors were "harrowing," Epstein says. He cites a patient referred to Hopkins with cancer of the ear canal. "The patient in this case would've had his middle ear removed, in an undeniably mutilating surgery. But with the second path report, the patient was found to have a fungal infection that responded well to treatment."

An earlier study at Hopkins that focused only on interpretation of prostate biopsies -- with a similar rate of faulty reports -- showed the second opinion canceled prostate surgery for six out of 535 cases, at a savings of almost $2 for every dollar spent on the second workup.

Both studies show that suspect or incorrect path reports come from a variety of sources. "We received them from community hospitals, commercial laboratories and large teaching institutions," says Epstein. Nor was Hopkins immune. In seven cases, an additional pathology review at Hopkins supported the patient's original report.

It's easy, Epstein says, to blame changes in the health care system for the problem. "In today's medicine, when HMOs and hospitals are looking to cut costs, doing a second look has come under attack. A second opinion is often viewed as an added administrative burden for overworked clinicians."

But the root of the misdiagnoses, he explains, may be advances in technology -- the needle biopsies, PSAs and improved radiology made to nip conditions in the bud. "With earlier diagnosis of suspect tissue, it's now much more difficult, for example, to separate out the mimics from the true cancers. Also, we used to get larger samples of tissue to evaluate; now we get needle biopsies of brain, breast, lymph nodes and prostate glands. That's good for patient recovery from the sampling procedure, but harder for the pathologist."

What the Hopkins pathologists recommend is that institutions set up policies requiring a review of the original biopsies before patients undergo surgery or other major therapy. "Patients, too, should recognize that a pathologist is a human capable of mistakes," says Epstein. "Evaluating tissue isn't a machine-like process where everything comes out 100 percent correct. So it's worth patients' while to get a second review of the pathology, just as they'd get a second surgeon's opinion."

Other researchers in the study are Joseph D. Kronz, M.D., and William H. Westra, M.D.
-end-
Related Web site: http://www.path.jhu.edu/
The Hopkins study appeared in Cancer, Dec. 1, 1999, vol. 86, no. 11 pp 2426-2435.

Media Contact: Marjorie Centofanti 410-955-8725
Email: mcentofanti@jhmi.edu

Johns Hopkins Medical Institutions' news releases are available on an EMBARGOED basis on EurekAlert at http://www.eurekalert.org, Newswise at http://www.newswise.com and from the Office of Communications and Public Affairs' direct e-mail news release service. To enroll, call 410-955-4288 or send e-mail to bsimpkins@jhmi.edu.

On a POST-EMBARGOED basis find them at http://hopkins.med.jhu.edu, Quadnet at http://www.quad-net.com and ScienceDaily at http://www.sciencedaily.com.

Johns Hopkins Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.